Abstract
Alcohol use disorder is associated with several mental, physical, and social problems. Its treatment is difficult and often requires a combination of pharmacological and behavioural therapy. The brain histaminergic system, one of the wake-active systems that controls whole-brain activity, operates through three neuronal GPCRs. The histamine H-3 receptor (Hrh3), which is expressed in many brain areas involved in alcohol drinking and alcohol reward, can be targeted with a number of drugs developed initially for cognitive disorders and/or disorders related to sleep, wakefulness, and alertness. In all rodent alcohol drinking models tested so far, H-3 receptor antagonists have reduced alcohol drinking and alcohol-induced place preference and cue-induced alcohol reinstatement. Several H-3 receptor antagonists tested and found to be safe for humans could be subjected to clinical tests to treat alcohol use disorder. Preference should be given to short-acting drugs to avoid the sleep problems associated with the wake-maintaining effects of the drugs.
Linked Articles This article is part of a themed section on New Uses for 21st Century. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.3/issuetoc
Original language | English |
---|---|
Journal | British Journal of Pharmacology |
Volume | 177 |
Issue number | 3 |
Pages (from-to) | 634-641 |
Number of pages | 8 |
ISSN | 0007-1188 |
DOIs | |
Publication status | Published - 22 Feb 2020 |
MoE publication type | A2 Review article in a scientific journal |
Fields of Science
- 317 Pharmacy
- VENTRAL TEGMENTAL AREA
- CONDITIONED PLACE PREFERENCE
- COGNITIVE-BEHAVIORAL THERAPY
- MU-OPIOID-RECEPTOR
- H3 RECEPTOR
- DOPAMINERGIC-NEURONS
- NUCLEUS-ACCUMBENS
- SUBSTANTIA-NIGRA
- GENE-EXPRESSION
- CONCISE GUIDE